Study of the protective efficacy of CombiMab-2 against human immunodeficiency virus type 1 in mice humanised with CD4<sup>+</sup> T-lymphocytes

Study of the protective efficacy of CombiMab-2 against human immunodeficiency virus type 1 in mice humanised with CD4<sup>+</sup> T-lymphocytes

INTRODUCTION. Despite existing treatment methods, complete eradication of human immunodeficiency virus (HIV) infection remains an unattainable goal due to the high variability of HIV type 1 (HIV-1). HIV infection necessitates life-long administration of antiretroviral medicinal products, which cause...

Full description

Saved in:
Bibliographic Details
Main Authors: D. S. Leontyev, F. A. Urusov, D. V. Glazkova, B. V. Belugin, O. V. Orlova, R. R. Mintaev, G. M. Tsyganova, E. V. Bogoslovskaya, G. A. Shipulin
Format: Article
Language:Russian
Published: Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2024-10-01
Series:Биопрепараты: Профилактика, диагностика, лечение
Subjects:
humanised mice
human immunodeficiency virus type 1
hiv-1
cd4+ t-lymphocytes
adenoassociated virus
aav vector
gene therapy
broadly neutralising antibodies
protective efficacy
antiviral activity
Online Access:https://www.biopreparations.ru/jour/article/view/599
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items